Navigation Links
Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
Date:10/26/2008

- Ninety-six week ARTEMIS data presented at ICAAC -

BRIDGEWATER, N.J., Oct. 26 /PRNewswire/ -- Ninety-six week results presented today from a phase 3, randomized, open-label, ongoing clinical trial showed that 79 percent of treatment-naive HIV-1 infected adults taking PREZISTA(R) 800 mg (two 400 mg tablets) with 100 mg ritonavir (r) once daily reached an undetectable viral load (<50 copies/mL) at week 96, compared with 71 percent of patients taking lopinavir/ritonavir 800 mg/200 mg once daily (or 400 mg/100 mg twice daily), each with a fixed dose of emtricitabine and tenofovir disoproxil fumarate.

Results from the study, known as ARTEMIS, were presented today at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. ARTEMIS is a 192-week study comparing the efficacy and safety of the protease inhibitors (PIs) PREZISTA/r and lopinavir/r in treatment-naive adults with HIV (those who have never taken HIV medication before). PREZISTA was developed by Tibotec Pharmaceuticals and is marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.

At 48 weeks, the primary objective of ARTEMIS was reached when PREZISTA/r was demonstrated to be non-inferior to lopinavir/r for virologic response (confirmed HIV RNA < 50 copies/mL). The difference between the treatment arms was not significant at week 48. The pre-planned safety and efficacy analysis at 96 weeks was a secondary endpoint. At 96 weeks, the study showed PREZISTA/r was non-inferior to lopinavir/r for virologic response. The estimated difference in virologic response between the treatment groups was eight percent and was statistically significant (95 percent confidence interval 1.8; 14.7). The 96-week results from ARTEMIS will be submitted to the FDA.

"This study offers the healthcare provider community long-term efficacy and safety data for PREZISTA in treatment-naive adult patients," said Tony Mills, M.D., ART
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Drug development for hepatitis ... incidence rates and the intense need for curative ... Change is underway as the market moves away ... effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first of ...
(Date:7/29/2014)... 29, 2014  Cloud Pharmaceuticals, Inc., a therapeutics ... announced today that it has been awarded a ... Small Business Innovation Research (NSF SBIR) program. The ... Cloud Pharmaceuticals designs new drugs and drug candidates ... innovative cloud computing technology in place of traditional ...
(Date:7/29/2014)... , July 29, 2014  Encision Inc. (OTCQB:ECIA), a ... dangerous stray electrosurgical burns in minimally invasive surgery, today ... ended June 30, 2014. The Company posted ... net loss of $202 thousand, or $(0.02) per share. ... for a net loss of $311 thousand, or $(0.04) ...
Breaking Medicine Technology:A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Cloud Pharmaceuticals Receives Phase I NSF SBIR Grant Valued at $150,000 2Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4
... Pfizer Inc. (NYSE: PFE ) announced ... Capsugel, which may include a divestiture.  Capsugel is ... segment and is the world,s leading provider of ... systems. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
... LAKE, N.J., Oct. 6, 2010 Arena Pharmaceuticals, Inc. ... today upcoming lorcaserin presentations at Obesity 2010, the 28th ... Diego, California. Lorcaserin, which Arena discovered and developed, is ... of weight loss, in patients who are obese (Body ...
Cached Medicine Technology:Pfizer To Review Strategic Alternatives For Capsugel 2Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 2Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 3Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 4
(Date:7/29/2014)... contact lenses may seem like a fun accessory, but ... damage. Decorative contacts should be fitted properly by ... and Drug Administration (FDA). It,s important to get an ... and buy them from a trustworthy seller, the FDA ... health risks associated with decorative contact lenses, the FDA ...
(Date:7/29/2014)... 2014 The Transformer Oil Market in Europe ... with analysis and forecast of revenue. The Transformer Oil market ... in 2013 to $0.5 billion by 2018, at a CAGR ... TOC of the Transformer Oil Market in Europe report, to ... provides a glimpse of the segmentation in the Transformer Oil ...
(Date:7/29/2014)... Pediatric AIDS Foundation (EGPAF) and the American Cancer Society ... essential pain medications for people living with HIV in ... initiative, this new partnership will help improve efforts to ... country. , Swaziland has the highest HIV prevalence ... adults ages 15-49 infected. Many of these individuals also ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Regents Health ... imaging services, has brought health care industry veteran Daryl ... board to help lead the company’s ambitious plans to ... “Regents Health has been moving along at a steady ... kick it up a notch,” says Bob Maier, founder ...
(Date:7/29/2014)... Test instruments after processing to assure ... where it matters most – on the surgical ... premium domestic appliances, introduces ProCare Protein Check, a ... cleaned. The ProCare liquid is applied directly to ... After 3 minutes, users visually determine the presence ...
Breaking Medicine News(10 mins):Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2
... significant effect for the more serious, bacterial form of the ... increasingly used to help treat children with bacterial meningitis, but ... treatment may not reduce death rates or the length of ... 2,780 children treated for this potentially lethal infection of tissues ...
... & Vote at,SEIU Hearing, MANHATTAN BEACH, Calif., May ... Employees International Union (SEIU),intensified today as the first in ... of more than 60,000 long-term caregivers who are members,of ... in hospitals, clinics, nursing homes, and home care throughout,California., ...
... U.S. Preventive Medicine(R), (http://www.USPreventiveMedicine.com ) the leader in ... banking team, composed of Credit,Suisse, Deutsche Bank, Merrill ... term capital strategy, mergers and acquisition efforts in ... ), "The selection of some of the ...
... women make it not just a ,man,s disease, anymore ... alcohol dependence has increased substantially among women, particularly white ... finds. , Alcohol use and dependency appeared to ... more lifetime alcohol problems than older Americans, despite having ...
... ADAMS, Mass., May 6 The Lucian Leape Institute ... the,appointment of two new Institute Members: James A. Guest ... Patient Safety,Foundation(R) (NPSF) in May 2007, is a think ... for the field of patient safety. Its,goal is to ...
... ... System, ... and Utilization Review Physicians, Inc. (ABQAURP) is sponsoring,the 3rd Annual Medical ... individuals with chronic or,high-cost conditions. The symposium is scheduled for June ...
Cached Medicine News:Health News:Corticosteroids of Little Use Against Childhood Meningitis 2Health News:Corticosteroids of Little Use Against Childhood Meningitis 3Health News:SEIU Retaliates Against California Caregivers & Democratic Reform Movement 2Health News:U.S. Preventive Medicine Announces Investment Banking Team 2Health News:Alcoholism Gender Gap Is Closing 2Health News:Alcoholism Gender Gap Is Closing 3Health News:The Lucian Leape Institute at the National Patient Safety Foundation Announces the Appointment of Two New Members 2Health News:ABQAURP Hosts Third Annual Medical Management Conference in Orlando 2
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
... BchiVac V-500 with Vacuum Controller V-800 Efficiently ... turns V-500 on and off as needed to maintain ... Model V-500 is a powerful PTFE membrane vacuum pump ... Ideally suited for use with up to two ...
... V-1000 is a new addition to the powerful ... high performance pump can achieve an ultimate vacuum ... 64 L/min. Applications For use ... Distillation applications from lab size up ...
... is a powerful PTFE membrane vacuum pump designed ... Ideally suited for use with up to ... for instruments including vacuum ovens, concentrators, gel dryers, ... PEEK head resistant to chemicals and heat ...
Medicine Products: